| Symbol | ADMA |
|---|---|
| Name | ADMA BIOLOGICS, INC. |
| Sector | HEALTH CARE |
| Region | UNDEFINED |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | C/O ADMA BIOLOGICS, INC., RAMSEY, NJ 07446 |
| Telephone | (201) 478-5552 |
| Fax | — |
| — | |
| Website | https://www.admabiologics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. Additional info from NASDAQ: |
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Read moreADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Read moreSecurities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Read moreNew Form ARS - ADMA BIOLOGICS, INC. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001140361-26-014803 <b>Size:</b> 3 MB
Read moreNew Form DEFA14A - ADMA BIOLOGICS, INC. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001140361-26-014801 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - ADMA BIOLOGICS, INC. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001140361-26-014799 <b>Size:</b> 6 MB
Read moreADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Read moreADMA Fraud Notice: ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop — BFA Law
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05070455 | An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and… | Phase4 | Primary Immune Deficiency | Unknown | 2022-09-01 | 2023-06-30 | ClinicalTrials.gov |
| NCT03164967 | Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Def… | Phase4 | Humoral Immune Response | Completed | 2016-12-29 | 2022-12-31 | ClinicalTrials.gov |
| NCT03037359 | A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Dise… | — | Primary Immune Deficiency Disorder | Unknown | 2016-12-01 | 2023-06-30 | ClinicalTrials.gov |
| NCT01814800 | Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With … | Phase3 | Primary Immune Deficiency Disorder | Completed | 2014-02-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00632463 | RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients … | Phase2 | Upper Respiratory Tract Infection | Completed | 2008-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00538915 | Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human… | Phase3 | Primary Immune Deficiency Disorders (PIDD) | Completed | 2007-09-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00473824 | Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), C… | Phase2 | Sequelae of Viral Hepatitis | Terminated | 2007-05-01 | 2009-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Asceniv™ | BIOLOGICAL | Phase PHASE4 | Primary Immune Deficiency | UNKNOWN | NCT05070455 |
| Other | BIOLOGICAL | Preclinical | Primary Immune Deficiency Disorder | UNKNOWN | NCT03037359 |
| Bivigam | BIOLOGICAL | Phase PHASE4 | Humoral Immune Response | COMPLETED | NCT03164967 |
| RI-002 | BIOLOGICAL | Phase PHASE3 | Primary Immune Deficiency Disorder | COMPLETED | NCT01814800 |
| Hepatitis C Immune Globulin Intravenous (Human) 5% | BIOLOGICAL | Phase PHASE2 | Sequelae of Viral Hepatitis | TERMINATED | NCT00473824 |
| RI-001 | BIOLOGICAL | Phase PHASE2 | Upper Respiratory Tract Infection | COMPLETED | NCT00632463 |
| Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] | BIOLOGICAL | Phase PHASE3 | Primary Immune Deficiency Disorders (PIDD) | COMPLETED | NCT00538915 |